Philip D.  Gregory net worth and biography

Philip Gregory Biography and Net Worth

Insider of 2seventy bio
Philip D. Gregory, D.Phil., is chief scientific officer at 2seventy bio. Previously, Philip served as chief scientific officer at bluebird bio for over six years. Philip was formerly with Sangamo BioSciences, where he held multiple leadership positions over a nearly 15-year tenure, most recently serving as chief scientific officer and senior vice president, research. In this role, he was responsible for the scientific direction and strategic research planning for the company. Philip played an integral role in Sangamo’s partnerships and drove early discovery and development for several IND candidates in multiple therapeutic areas. Prior to joining Sangamo, he was a postdoctoral fellow at Ludwig-Maximilians-Universität München. Philip holds a D.Phil in biochemistry from Oxford University, Keble College and a B.Sc. in microbiology from Sheffield University.

What is Philip D. Gregory's net worth?

The estimated net worth of Philip D. Gregory is at least $904,900.64 as of January 5th, 2024. Dr. Gregory owns 230,842 shares of 2seventy bio stock worth more than $904,901 as of November 15th. This net worth estimate does not reflect any other investments that Dr. Gregory may own. Learn More about Philip D. Gregory's net worth.

How do I contact Philip D. Gregory?

The corporate mailing address for Dr. Gregory and other 2seventy bio executives is , , . 2seventy bio can also be reached via phone at 339-499-9300 and via email at [email protected]. Learn More on Philip D. Gregory's contact information.

Has Philip D. Gregory been buying or selling shares of 2seventy bio?

Philip D. Gregory has not been actively trading shares of 2seventy bio over the course of the past ninety days. Most recently, Philip D. Gregory sold 795 shares of the business's stock in a transaction on Friday, January 5th. The shares were sold at an average price of $3.75, for a transaction totalling $2,981.25. Following the completion of the sale, the insider now directly owns 230,842 shares of the company's stock, valued at $865,657.50. Learn More on Philip D. Gregory's trading history.

Who are 2seventy bio's active insiders?

2seventy bio's insider roster includes William Baird, III (CFO), Philip Gregory (Insider), Nicola Heffron (COO), and Nick Leschly (CEO). Learn More on 2seventy bio's active insiders.

Are insiders buying or selling shares of 2seventy bio?

During the last twelve months, 2seventy bio insiders bought shares 2 times. They purchased a total of 630,000 shares worth more than $3,143,100.00. During the last twelve months, insiders at the sold shares 11 times. They sold a total of 144,965 shares worth more than $564,664.26. The most recent insider tranaction occured on August, 14th when insider Jessica Snow sold 7,816 shares worth more than $33,765.12. Insiders at 2seventy bio own 7.2% of the company. Learn More about insider trades at 2seventy bio.

Information on this page was last updated on 8/14/2024.

Philip D. Gregory Insider Trading History at 2seventy bio

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/5/2024Sell795$3.75$2,981.25230,842View SEC Filing Icon  
1/3/2024Sell25,613$3.87$99,122.31231,637View SEC Filing Icon  
8/22/2023Sell6,159$5.49$33,812.91257,250View SEC Filing Icon  
8/3/2023Sell3,966$6.13$24,311.58263,409View SEC Filing Icon  
1/11/2023Sell1,076$10.63$11,437.8899,518View SEC Filing Icon  
1/9/2023Sell3,794$10.33$39,192.02100,594View SEC Filing Icon  
8/5/2022Sell2,407$16.23$39,065.61104,388View SEC Filing Icon  
7/15/2022Sell2,365$13.81$32,660.65106,795View SEC Filing Icon  
1/7/2022Sell1,452$23.91$34,717.32View SEC Filing Icon  
See Full Table

Philip D. Gregory Buying and Selling Activity at 2seventy bio

This chart shows Philip D Gregory's buying and selling at 2seventy bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

2seventy bio Company Overview

2seventy bio logo
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $3.92
Low: $3.90
High: $4.32

50 Day Range

MA: $4.74
Low: $4.13
High: $5.21

2 Week Range

Now: $3.92
Low: $1.53
High: $6.40

Volume

283,585 shs

Average Volume

313,004 shs

Market Capitalization

$202.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.78